Valuation: Karyopharm Therapeutics Inc.

Market Cap 578K 523K 483K 437K 825K 54.37M 849K 5.79M 2.3M 29.07M 2.17M 2.12M 92.52M P/E 2026 *
-0.01x
P/E 2027 * -0.01x
Enterprise Value 578K 523K 483K 437K 825K 54.37M 849K 5.79M 2.3M 29.07M 2.17M 2.12M 92.52M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.35%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Karyopharm Therapeutics Inc.

1 day+45.71%
1 week-57.57%
Current month-96.15%
1 month-94.95%
3 months-98.74%
6 months-99.71%
Current year-99.65%
1 week 0.01
Extreme 0.008
0.04
1 month 0.01
Extreme 0.008
0.99
Current year 0.01
Extreme 0.008
10.99
1 year 0.01
Extreme 0.008
10.99
3 years 0.01
Extreme 0.008
29.25
5 years 0.01
Extreme 0.008
220.95
10 years 0.01
Extreme 0.008
444.15
Manager TitleAgeSince
Chief Executive Officer 58 03/05/2021
Director of Finance/CFO 55 03/01/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Director/Board Member 63 01/01/2013
Director/Board Member 61 01/04/2013
Director/Board Member 78 03/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/26 Sell

Controller/Auditor

-4,788 0.0211%
1/10/26 Sell

Controller/Auditor

-378 0.0017%
1/9/26 Sell

Controller/Auditor

-19 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+45.71%-57.57%-99.54%-99.76% 578K
-0.70%+4.58%+40.23%+138.79% 1,271B
+1.11%+4.11%+45.85%+92.54% 683B
-0.18%+2.15%+26.25%+112.46% 520B
-0.65%+3.36%+39.15%+68.96% 389B
-0.16%+0.01%+60.69%+44.94% 362B
-0.04%+0.72%+26.76%+58.40% 304B
+0.17%+0.09%+3.32%+36.05% 286B
-0.22%+1.47%+38.89%+74.73% 253B
-1.05%+0.23%+36.10%+121.22% 208B
Average +4.47%-4.20%+21.77%+64.83% 428B
Weighted average by Cap. -0.01%+2.67%+37.36%+96.68%

Financials

2026 *2027 *
Net sales 134M 122M 112M 102M 192M 12.63B 197M 1.35B 535M 6.75B 504M 494M 21.5B 160M 145M 133M 121M 228M 15.03B 235M 1.6B 637M 8.04B 600M 587M 25.58B
Net income -156M -141M -130M -118M -222M -14.67B -229M -1.56B -621M -7.84B -585M -573M -24.96B -116M -105M -97.15M -87.93M -166M -10.94B -171M -1.17B -463M -5.85B -437M -427M -18.62B
Net Debt - -
Projected Income Statement - Annual - Karyopharm Therapeutics Inc.
Logo Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Employees
228
Date Price Change Volume
12/11/26 USD 0.0255 +45.71% 2,711,602
11/11/26 USD 0.0175 +0.57% 8,281,735
10/11/26 USD 0.0174 -56.50% 146,821,550
09/11/26 USD 0.0400 -27.14% 23,722,490
06/11/26 USD 0.0549 -8.65% 104,537,597
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Karyopharm Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0255USD
Average target price
7.000USD
Spread / Average Target
+27,350.98%
  1. Stock Market
  2. Stocks
  3. KPTI Stock